Bridging the Gap Between Regulatory Capital and Insurance Capacity. For financial institutions under Basel III/IV, insurance is no longer only a risk management expense—it can be a substitute for equity capital.
We do not treat captives, reinsurance, or securitisation as isolated products. We treat them as integrated levers in a Capital Engineering Framework—transforming the balance sheet by arbitrating the cost difference between holding regulatory capital (expensive) and transferring risk to insurance markets (efficient).
Our objective is to unlock Capital Velocity—recycling capital to support new lending without raising expensive equity.
We differentiate by integrating the captive directly into the capital relief chain. We do not only place insurance—we engineer a flow of funds that retains economics within the group.
This turns a cost centre (premiums) into a profit centre (captive dividends) while delivering the capital relief CFOs need.
Capital markets move faster than licensing timelines. We use Protected Cell Companies (PCCs) and Segregated Account Companies (SACs) as tactical “plug-and-play” infrastructure.
Regulators (ECB, PRA) scrutinise synthetic structures to ensure they represent genuine risk transfer—not accounting arbitrage. We design and document structures to pass the substance test.
We operate at the intersection of Basel IV regulation, corporate finance, and reinsurance. Unlike traditional brokers focused on placement—or captive managers focused on administration—Berrizal Partners focuses on the balance sheet.
Reduce RWA density through eligible Unfunded Credit Protection and supervisory-robust structures.
Capture underwriting margins through captive reinsurance within a compliant fronting chain.
Deploy tactical cell facilities for rapid SRT and portfolio-specific risk transfer.
We can evaluate whether UFCP, captive integration, and SRT structures can reduce RWA and improve RAROC—subject to jurisdiction and supervisory review.